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Abstract
Background Refractory status epilepticus (RSE) treat-
ment is usually performed with comainduction using an
appropriate general anesthetic. Most frequent complica-
tions are represented by hypotension and infection. Other
side-effects may however be encountered.
Observations We describe two patients suffering from
acute bowel ischemia after thiopental (THP) treatment for
RSE. A 73-year-old man with a complex-patial RSE fol-
lowing an acute stroke received THP (303 mg/kg over
48 h); 36 h after THP discontinuation, he presented
abdominal tenderness and lactate elevation. Necrosis of
the terminal ileum and colon was seen during surgical
exploration; he deceased shortly thereafter. A 21 year-old
woman had a cryptogenic de novo generalized-convulsive
RSE resistant to 5 attempts of EEG burst-suppression.
During the 6th attempt, after THP (840 mg/kg over 150 h)
together with mild hypothermia, she developed an ileus
with elevated serum lactate; caecum necrosis was observed
during surgery. Hypernatremia, acidosis and hyperlactat-
emia heralded this complication in both patients.
Conclusion In these two patients, mechanical vascular
ischemia may have resulted from drug-induced paralytic
ileus. To our knowledge, this is the first report describing
this potential fatal side effect in adults with RSE.
Keywords Thiopental  Epilepsy 
Refractory status epilepticus  Bowel ischemia
Status epilepticus (SE) has a yearly incidence of 10 to 41/
100,000 and is the second most common life-threatening
neurological emergency after stroke [1]. Refractory status
epilepticus (RSE) is considered when administration of
benzodiazepines and second line AEDs (e.g. phenytoin,
valproic acid, or phenobarbital) fail to control SE [2].
Treatment of RSE aims at EEG background suppression
with an appropriate anesthetic agent, such as midazolam,
propofol, or barbiturates (thiopental (THP) in Europe; or
pentobarbithal in North America) [3, 4]. Most cited com-
plications related to these agents are represented by arterial
hypotension, ‘‘infusion syndrome’’, or infections [3, 5, 6].
We report here on two patients with RSE, who underwent
THP treatment for RSE and suffered from acute bowel
ischemia, which appears to represent a rare but potentially
fatal complication.
Patient 1
A 73-year-old man presented an acute-onset language
disturbance and was admitted to our emergency depart-
ment. His past medical history was characterized by
chronic hepatitis C leading to cirrhosis (Child B), as well as
a valvular cardiopathy treated with diuretics. On arrival, he
displayed fluent aphasia with a severe understanding defi-
cit. A brain computer tomography with perfusion images
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showed an acute left parieto–occipital stroke and a chronic
left frontal ischemic lesion. Shortly thereafter, he had a
generalized tonic clonic seizure; he received 1 mg clona-
zepam i.v. An EEG showed continuous epileptiform
activity in the left temporal area with periodic lateralized
epileptiform discharges (PLEDs). The patient subsequently
developed repetitive complex-partial seizures (right hemi-
body clonic convulsions with right sided nystagmus and
consciousness impairment). Despite treatment with intra-
venous lorazepam, phenytoin, and valproate, at therapeutic
serum levels, his condition worsened, with progressive
consciousness impairment and language disturbances; a
persistent epileptic activity was observed on follow-up
EEGs. After 72 h, with the diagnosis of complex-partial
RSE, he was electively transferred to the intensive care
unit, and an EEG burst-suppression pattern was achieved
with a THP drip (total dose: 303 mg/kg over 48 h); base-
line AED treatment was continued. Thirty-six hours after
THP discontinuation and after more than 72 h of burst-
suppression, the still comatose patient had a sudden ele-
vation of lactate levels (peaking at 10.5 mmol/l),
associated with new-onset peritonismus. Of note, he did not
experience significant arterial hypotension (because he was
under norepinephrine administration) during THP treat-
ment and thereafter. An emergency surgical exploration
showed an extensive, fresh necrosis of the terminal ileum
and of the left and right colon until the recto-sigmoid
junction. The bioptic material did not show any vascular
lesion (thrombotic or inflammatory). Still in the operation
room, he developed a septic shock and died 12 h after the
intervention. Data regarding thiopental therapy and perti-
nent clinical findings are given in Table 1.
Patient 2
A 21-year-old woman with a complete negative medical
history was admitted after a viral upper airways infection to
the intensive care unit, because of de novo complex-partial
seizures (right facial myoclonus with consciousness alter-
ation) followed by secondary generalized SE. Etiology
remained undetermined despite exhaustive investigations:
several brain MRI and CSF examinations, as well as
extended infectious, immunological, and metabolic disor-
ders screenings were repeatedly negative. Her SE was
resistant to an initial treatment of intravenous high-dosage
clonazepam, phenytoine, valproate, levetiracetam, and oral
topiramate (administered through the nasogastric tube).
She also did not respond to five courses of EEG burst-
suppression attempts (with propofol (up to 10 mg/kg/h);
thiopental (6–8 mg/kg/h); ketamine (up to 12 mg/kg/h)
combined with midazolam (0.5 mg/kg/h); THP (6–8 mg/
kg/h); propofol (4–7 mg/kg/h) combined with midazolam
(0.5–0.8 mg/kg/h)), targeting burst-suppression for at least
24 h, and up to 7 days, and periodically weaning the
anesthetics to observe EEG and clinical evolution. During
the sixth attempt, after more than 2 months of ICU treat-
ment, THP was administered together with mild
hypothermia (34C), which was achieved with an external
cooling, and other AED (see Table 1) in order to obtain a
transitory complete EEG suppression. Daily THP dosage
was reduced stepwise after the first 48 h; she received a
total dose of 840 mg/kg over 150 h. No systemic arterial
hypotension was noted (under norepinephrine administra-
tion). On the sixth day (after THP discontinuation), she
developed an ileus with elevated serum lactate (peaking at
Table 1 Demographical and
clinical data of the two patients
AED antiepileptic drugs, BS
burst-suppression; CLZ
clonazepam, LZP lorazepam,
PHT phenytoin, RSE refractory
status epilepticus, THP
thiopental, TPM topiramate,
VPA valproate
Patient 1 2
Gender M F
Age (years) 73 21
Weight (kg) 65 58
RSE type Complex partial Secondary generalized
RSE etiology Acute stroke Cryptogenic
Duration of THP administration (h) 48 150
Total THP dose (mg/kg) 303 840
Highest daily THP dose (g) 12 9
Highest THP infusion rate (mg/kg/h) 15 8
Concomitant norepinephrine administration rate (lg/min) 10–20 10–20
Sodium maximal level 12 h before surgery (mmol/l) 150 152
AED co-medication LZP, PHT, VPA CLZ, PHT, TPM
Latency BS end—lactate peak (h) 72 0
Lactate peak (norm < 1.5 mmol/l) 10.5 5.6
Lowest arterial pH 7.36 7.22
Final outcome Dead Refractory epilepsy
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5.6 mmol/l); her body temperature at this time was 36.5C.
The visceral surgeon described a megacolon with focal
cecum necrosis, but no sign of vascular or inflammatory
changes was noted on histological examination. After a
partial right colon resection, the patient recovered follow-
ing a seventh burst-suppression treatment with propofol
coupled with midazolam. At 12 months follow-up, she still
has refractory, complex-partial seizures, and a marked
neuropsychological impairment. A representation of thio-
pental therapy and other clinical findings are seen in
Table 1.
Discussion
These two patients developed intestinal ischemia during
RSE treatment and after high-dose THP administration;
both patients were fed enterally during THP administration
and thereafter. While SE etiology in the first subject was
related to his acute stroke, the second patient probably had
‘‘de novo’’ SE, which often proves very difficult to treat [7]
and is probably related to inflammatory or infectious cau-
ses [8].
Ileus represents a relatively rare side effect of high-
dose barbiturates, occurring in about 10% of patients
according to a recent series [9]. However, to the best of
our knowledge, it has only been anecdotally described in
the context of RSE treatment in children treated with THP
[10], but without complications such as intestinal infarc-
tion or death. Of note, adult RSE series do not mention
this complication [3, 5]. In our center, we treat RSE
preferentially with propofol since 10 years (more than 50
cases to date), and so far we did not observe ileus in this
setting [11]. Intestinal infarction complicating barbiturates
administration has been also rarely reported: a 29-year-old
patient presented a non-occlusive intestinal ischemia after
oral phenobarbital overdose. The proposed mechanism
was a combination of mild arterial hypotension, hypo-
thermia (rectal temperature, 33.3C), hypoxemia (due to a
presumed respiratory arrest), and hemoconcentration. The
absence of co-morbidity and the young age were dis-
cussed as the principal factors explaining the full recovery
[12].
Reports of intestinal ischemia associated with SE
(regardless of the treatment) are also exceptional. A 19-
year-old woman presented with SE (and cardiac ventricular
arrhythmias) after massive ingestion of an antihistaminic
compound (5 g of dimenhydrinate) in a suicidal attempt.
Despite maximal supportive treatment, she developed
bowel ischemia necessitating a colonic resection. After
surgery, her condition worsened and following demon-
stration of minimal cerebral activity, supportive measures
were eventually withdrawn [13]. There was no mention of
barbiturates administration, and it appears plausible that
the ingested drug contributed to her ileus.
In intensive care medicine and anesthesiology, non-
occlusive mesenteric ischemia (NOMI) is a relatively
common disorder [14], and is encountered in conditions
such as exposure to toxic amounts of vasoactive drugs
(including ergotamine, digitalis) with an underlying car-
diovascular and renal disease in critically ill patients, or
during major operations. While our first patient had a well
compensated valvular cardiopathy, the second one was
previously healthy, and in both administration of norepi-
nephrine was performed to compensate for the known
hypotensive effect of THP [3]. The mechanism underlying
NOMI is probably multifactorial, including large vessel
vasoconstriction, which might be the consequence of the
action of various drugs (e.g., sympathomimetics or digi-
talis), and hypoperfusion of mesenteric arteries (anemia,
severe hypoxia, cardiovascular shock, sepsis). NOMI is
strongly associated with a dismal prognosis [14].
Although the underlying mechanism in our patients
remains unproven, we suggest the etiological role of
THP-induced paralytic ileus, possibly complicated by
hypothermia in the second subject. Of note, there are very
few patients with RSE treated with hypothermia reported in
the literature, but ileus does not seem to be very common
[15]. Histological examination in our patients failed to
show any inflammatory or atherosclerotic change, and no
suspicion of abdominal compartment syndrome was men-
tioned by the surgeons. Table 1 shows that both subjects
received a high THP load: the total dose was considerably
higher as compared to that normally used for neuropro-
tection after traumatic brain injury [16]. The latency
between the weaning of THP administration and ileus
diagnosis may be explained by the very long elimination
THP half-life following redistribution into the fat tissue
[17]. Furthermore, our two patients shared a distinctive
metabolic profile preceding the event, with hypernatremia
(probably as a result of sodium THP administration)
together with acidosis and hyperlactatemia. Despite lactate
elevation, a ‘‘thiopental infusion syndrome’’ seems unli-
kely, given the absence of other signs of this complication
(rhabdomyolysis, myocardial failure) [18]. Regardless of
the precise etiology, selective attention to these parameters
and clinical abdominal survey appear mandatory in order to
detect early this rare but potentially fatal complication.
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